

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Trpik Joseph R JR</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>05/10/2022</u>		3. Issuer Name and Ticker or Trading Symbol <u>EXELON CORP [EXC]</u>	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>SVP & Corp. Controller</u>		5. If Amendment, Date of Original Filed (Month/Day/Year)	
<u>10 S DEARBORN STREET</u> <u>54TH FLOOR</u>					6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(Street)						
<u>CHICAGO</u>	<u>IL</u>	<u>60603</u>				
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,662	D	
Common Stock (401k plan shares)	1,365	D	
Common Stock	6,271	I	Held by spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Restricted Stock Unit Award (01/27/2020)	(1)	(1)	Common stock	1,234 ⁽¹⁾	(1)	D
Restricted Stock Unit Award (01/25/2021)	(2)	(2)	Common stock	2,589 ⁽²⁾	(2)	D
Restricted Stock Unit Award (01/28/2022)	(3)	(3)	Common stock	2,871 ⁽³⁾	(3)	D
Restricted Stock Unit Award (05/02/2022)	(4)	(4)	Common stock	906 ⁽⁴⁾	(4)	D
Earned Performance RSU	(5)	(5)	Common stock	7,298 ⁽⁵⁾	(5)	D
Deferred Phantom Shares	(6)	(6)	Common stock	508 ⁽⁶⁾	(6)	D

Explanation of Responses:

- Remaining 1/3 increment of annual restricted stock unit (RSU) award granted in January 2020 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Remaining 2/3 increment of annual RSU award granted in January 2021 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Annual RSU award granted in January 2022 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Additional RSU award granted in May 2022 pursuant to the Exelon Long Term Incentive Plan; this award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- RSU award granted pursuant to the Exelon Long Term Incentive Plan; Award cliff vests at the January 2023 meeting of the Compensation Committee with each RSU representing the right to receive one share of Exelon common stock upon vesting. RSUs accrue quarterly dividend equivalents in the form of additional RSUs representing common stock dividends as approved by the Board, which vest on the same schedule as the underlying RSU.
- Phantom share equivalents representing units held in the Exelon stock fund in a multi-fund, non-qualified deferred compensation plan. The Exelon stock fund is a unitized fund that consists of Exelon common stock and short term investments. Units of the fund will be settled upon the reporting person's separation from the company for any reason. Units will be settled in cash. Units are acquired through regular periodic contributions, company matching contributions and the reinvestment of dividend equivalents. The balance of phantom share equivalents may fluctuate due to periodic changes in the fund composition.

Elizabeth M. Hensen, Attorney-in-Fact 05/16/2022
for Joseph Trpik, Jr.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sect

The undersigned hereby constitute
M. Hensen or Tom Boin signing sin

- (1) execute for and on behalf
director of Exelon Corpora
Section 16(a) of the Secu
(including EDGAR Form ID)
- (2) do and perform any and a
desirable to complete an
amendment or amendmen
and Exchange Commission
- (3) take any other action of an
of such attorney-in-fact, r
undersigned, it being unde

of the undersigned pursuant
terms and conditions as s

The undersigned hereby grants to
any and every act and thing what
of the rights and powers herein g
could do if personally present,
confirming all that such attorney-
do or cause to be done by virtue o
undersigned acknowledges that t
of the undersigned, are not assum
comply with Section 16 of the Sec

This Power of Attorney shall rema
file Section 16 Reports with respe
by Exelon, unless earlier revoke
attorneys-in-fact.

IN WITNESS WHEREOF, the u
as of this 22nd day of April, 2022.



By:

Name: Joseph R. Trpik, Jr.

